Second- and third-line therapy in gastric cancer/new options for therapy

被引：0
|
作者：
Schmalenberg, H. [1 ]
机构：
[1] Krankenhaus Dresden Friedrichstadt, Med Klin 4, Dresden, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V435
引用
收藏
页码：128 / 128
页数：1
相关论文
共 50 条
  • [31] A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
    Yoon-Koo Kang
    Kei Muro
    Min-Hee Ryu
    Hirofumi Yasui
    Tomohiro Nishina
    Baek-Yeol Ryoo
    Yukimasa Kamiya
    Shiro Akinaga
    Narikazu Boku
    Investigational New Drugs, 2014, 32 : 355 - 361
  • [32] Chemothery (pacitaxol or irinotecan), plus apatinib and sintilimab as second-/third-line treatment for advanced gastric cancer.
    Deng, Ting
    Zhang, Le
    Duan, Jingjing
    Li, Hongli
    Ge, Shaohua
    Bai, Ming
    Ning, Tao
    Yang, Yuchong
    Ji, Zhi
    Liu, Rui
    Wang, Xia
    Zhang, Haiyang
    Ba, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis
    Buchler, Tomas
    Bortlicek, Zbynek
    Poprach, Alexandr
    Kubackova, Katerina
    Kiss, Igor
    Zemanova, Milada
    Fiala, Ondrej
    Dusek, Ladislav
    Vyzula, Rostislav
    Melichar, Bohuslav
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (05) : 569 - 575
  • [34] Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Owonikoko, Taofeek K.
    Behera, Madhusmita
    Subramanian, Janakiraman
    Saba, Nabil F.
    Kono, Scott A.
    Gal, Anthony A.
    Sica, Gabriel
    Harvey, R. Donald
    Chen, Zhengjia
    Klass, Carmen M.
    Shin, Dong M.
    Fu, Haian
    Sun, Shi-yong R.
    Govindan, Ramaswamy
    Khuri, Fadlo R.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : 369 - 372
  • [35] Second- and third-line treatment for pediatric patients failing ART
    Giaquinto, C.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 21 : 68 - 68
  • [36] 'Tomudex' (raltitrexed) 4.0 mg/m[2] as second- or third-line therapy in patients with advanced colorectal cancer: A Phase II study
    Schulz, A
    Garfield, D
    Berry, W
    Gordon, D
    Lowery, C
    Smith, M
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S75 - S75
  • [37] Gemcitabine plus UFT combination chemotherapy as second- or third-line therapy in non-small cell lung cancer : a pilot study
    Nishimura, Naoki
    Sugiura, Rika
    Ueda, Hirotaka
    Ono, Hiroshi
    Horinouchi, Hidehito
    Uchiyama, Noboru
    Chohnabayashi, Naohiko
    JOURNAL OF MEDICAL INVESTIGATION, 2008, 55 (3-4): : 260 - 266
  • [38] Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer
    Jaime Coronel
    Lucely Cetina
    Myrna Candelaria
    Aurora González-Fierro
    Daimy Arias
    David Cantu
    Alfonso Dueñas-González
    Medical Oncology, 2009, 26 : 210 - 214
  • [39] Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer
    Coronel, Jaime
    Cetina, Lucely
    Candelaria, Myrna
    Gonzalez-Fierro, Aurora
    Arias, Daimy
    Cantu, David
    Duenas-Gonzalez, Alfonso
    MEDICAL ONCOLOGY, 2009, 26 (02) : 210 - 214
  • [40] Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer
    Brodowicz, T
    Kostler, WJ
    Möslinger, R
    Tomek, S
    Vaclavik, I
    Herscovici, V
    Wiltschke, C
    Steger, GG
    Wein, W
    Seifert, M
    Kubista, E
    Zielinski, CC
    BREAST, 2000, 9 (06): : 338 - 342
12345